Wednesday, November 11, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026 After Stock Surges 60%

ON Semiconductor issued guidance for AI data center revenue to double year-over-year in 2026, following a Q1 2026 earnings beat that drove a 60.1% stock surge over three months. The guidance signals accelerating demand for specialized chips powering AI infrastructure. Rising Treasury yields are tightening conditions broadly, but high-growth AI hardware names are proving resilient.

LM Salvado

May 20, 2026

ON Semiconductor Guides AI Data Center Revenue to Double in 2026 After Stock Surges 60%
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

ON Semiconductor guided AI data center revenue to double year-over-year in 2026, one of the most aggressive growth targets issued by a major chip supplier this cycle.1

The company's stock surged 60.1% over three months following its Q1 2026 earnings beat.1 That outperformance reflects a broader market repricing of semiconductor companies with direct AI infrastructure exposure.

AI data centers require power management chips, silicon carbide components, and intelligent sensing solutions — all areas where ON Semiconductor competes. The doubling guidance implies the company is seeing sustained order momentum from hyperscaler and cloud customers building out AI compute capacity.

Financial conditions are tightening in parallel. The 10-Year US Treasury benchmark rose from 4.31 to 5.0, a move that typically compresses equity valuations.1 High-growth AI hardware names have so far proven an exception, as investors treat AI infrastructure spending as non-discretionary.

Convertible debt markets are also shifting. ON Semiconductor's 2.50% Convertible Senior Notes saw a sharp repricing, with the relevant parameter dropping from 75.0 to 3.72 — consistent with restructuring activity seen across AI-adjacent balance sheets as companies optimize capital structures for a higher-rate environment.1

The divergence between AI-specific semiconductor names and the broader chip sector is becoming measurable. Companies with direct AI data center revenue lines — ON Semiconductor and Nvidia among them — are posting growth trajectories that general semiconductor indices are not matching. Whether that gap widens through Q3 2026 will depend on whether hyperscaler capex commitments translate into sustained silicon orders or front-loaded buying.

ON Semiconductor's doubled revenue guidance is the clearest public signal yet that AI hardware infrastructure investment has moved beyond early adoption into a sustained, multi-year buildout phase.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com